2023 Q3 Form 10-Q Financial Statement
#000110820523000060 Filed on August 03, 2023
Income Statement
Concept | 2023 Q3 | 2023 Q2 |
---|---|---|
Revenue | $2.833M | $2.197M |
YoY Change | 0.28% | -8.19% |
Cost Of Revenue | $60.00K | $74.00K |
YoY Change | -3.23% | 76.19% |
Gross Profit | $2.770M | $2.123M |
YoY Change | 0.25% | -9.7% |
Gross Profit Margin | 97.78% | 96.63% |
Selling, General & Admin | $4.760M | $4.249M |
YoY Change | 4.48% | -16.51% |
% of Gross Profit | 171.84% | 200.14% |
Research & Development | $10.38M | $10.01M |
YoY Change | -4.0% | -18.75% |
% of Gross Profit | 374.73% | 471.6% |
Depreciation & Amortization | $60.00K | $64.00K |
YoY Change | -1.64% | 45.45% |
% of Gross Profit | 2.17% | 3.01% |
Operating Expenses | $10.38M | $10.01M |
YoY Change | -4.0% | -18.75% |
Operating Profit | -$12.37M | -$12.14M |
YoY Change | -1.89% | -19.41% |
Interest Expense | $810.0K | $815.0K |
YoY Change | 141.79% | 403.09% |
% of Operating Profit | ||
Other Income/Expense, Net | $187.0K | $177.0K |
YoY Change | -127.18% | -120.14% |
Pretax Income | -$12.18M | -$11.96M |
YoY Change | -8.38% | -24.96% |
Income Tax | ||
% Of Pretax Income | ||
Net Earnings | -$12.18M | -$11.96M |
YoY Change | -8.37% | -24.96% |
Net Earnings / Revenue | -429.97% | -544.42% |
Basic Earnings Per Share | -$2.13 | -$0.12 |
Diluted Earnings Per Share | -$2.13 | -$0.12 |
COMMON SHARES | ||
Basic Shares Outstanding | 117.7M shares | 96.62M shares |
Diluted Shares Outstanding | 5.721M shares | 96.69M shares |
Balance Sheet
Concept | 2023 Q3 | 2023 Q2 |
---|---|---|
SHORT-TERM ASSETS | ||
Cash & Short-Term Investments | $68.50M | $63.49M |
YoY Change | -30.59% | -40.78% |
Cash & Equivalents | $24.47M | $19.82M |
Short-Term Investments | $44.00M | $43.67M |
Other Short-Term Assets | $2.100M | $1.978M |
YoY Change | -49.3% | -47.96% |
Inventory | ||
Prepaid Expenses | ||
Receivables | $2.848M | $2.386M |
Other Receivables | $0.00 | $0.00 |
Total Short-Term Assets | $73.43M | $67.85M |
YoY Change | -30.54% | -40.16% |
LONG-TERM ASSETS | ||
Property, Plant & Equipment | $497.0K | $561.0K |
YoY Change | -36.28% | -28.9% |
Goodwill | $8.982M | $8.982M |
YoY Change | 0.0% | 0.0% |
Intangibles | ||
YoY Change | ||
Long-Term Investments | ||
YoY Change | ||
Other Assets | $3.124M | $2.539M |
YoY Change | 54.5% | 299.84% |
Total Long-Term Assets | $16.55M | $16.46M |
YoY Change | -3.43% | 6.6% |
TOTAL ASSETS | ||
Total Short-Term Assets | $73.43M | $67.85M |
Total Long-Term Assets | $16.55M | $16.46M |
Total Assets | $89.98M | $84.31M |
YoY Change | -26.76% | -34.56% |
SHORT-TERM LIABILITIES | ||
YoY Change | ||
Accounts Payable | $5.221M | $2.686M |
YoY Change | -9.29% | -51.26% |
Accrued Expenses | $7.225M | $5.776M |
YoY Change | 4.97% | 3.61% |
Deferred Revenue | ||
YoY Change | ||
Short-Term Debt | $0.00 | $0.00 |
YoY Change | ||
Long-Term Debt Due | ||
YoY Change | ||
Total Short-Term Liabilities | $13.71M | $9.682M |
YoY Change | -0.25% | -20.32% |
LONG-TERM LIABILITIES | ||
Long-Term Debt | $0.00 | $0.00 |
YoY Change | ||
Other Long-Term Liabilities | $46.70M | $48.40M |
YoY Change | -12.49% | -11.41% |
Total Long-Term Liabilities | $46.70M | $48.40M |
YoY Change | -12.49% | -11.41% |
TOTAL LIABILITIES | ||
Total Short-Term Liabilities | $13.71M | $9.682M |
Total Long-Term Liabilities | $46.70M | $48.40M |
Total Liabilities | $60.38M | $58.08M |
YoY Change | -10.02% | -13.03% |
SHAREHOLDERS EQUITY | ||
Retained Earnings | -$1.200B | -$1.200B |
YoY Change | 9.09% | 9.09% |
Common Stock | $1.214B | $1.199B |
YoY Change | 1.7% | 0.99% |
Preferred Stock | ||
YoY Change | ||
Treasury Stock (at cost) | ||
YoY Change | ||
Treasury Stock Shares | ||
Shareholders Equity | $29.59M | $26.22M |
YoY Change | ||
Total Liabilities & Shareholders Equity | $89.98M | $84.31M |
YoY Change | -26.76% | -34.56% |
Cashflow Statement
Concept | 2023 Q3 | 2023 Q2 |
---|---|---|
OPERATING ACTIVITIES | ||
Net Income | -$12.18M | -$11.96M |
YoY Change | -8.37% | -24.96% |
Depreciation, Depletion And Amortization | $60.00K | $64.00K |
YoY Change | -1.64% | 45.45% |
Cash From Operating Activities | -$8.180M | -$7.868M |
YoY Change | -37.66% | -35.15% |
INVESTING ACTIVITIES | ||
Capital Expenditures | $0.00 | $0.00 |
YoY Change | -100.0% | -100.0% |
Acquisitions | ||
YoY Change | ||
Other Investing Activities | $180.0K | -$3.154M |
YoY Change | -95.87% | -110.99% |
Cash From Investing Activities | $180.0K | -$3.154M |
YoY Change | -95.82% | -111.13% |
FINANCING ACTIVITIES | ||
Cash Dividend Paid | ||
YoY Change | ||
Common Stock Issuance & Retirement, Net | ||
YoY Change | ||
Debt Paid & Issued, Net | ||
YoY Change | ||
Cash From Financing Activities | 12.56M | -852.0K |
YoY Change | 169.41% | 12.25% |
NET CHANGE | ||
Cash From Operating Activities | -8.180M | -7.868M |
Cash From Investing Activities | 180.0K | -3.154M |
Cash From Financing Activities | 12.56M | -852.0K |
Net Change In Cash | 4.560M | -11.87M |
YoY Change | -209.69% | -176.86% |
FREE CASH FLOW | ||
Cash From Operating Activities | -$8.180M | -$7.868M |
Capital Expenditures | $0.00 | $0.00 |
Free Cash Flow | -$8.180M | -$7.868M |
YoY Change | -37.41% | -33.2% |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
us-gaap |
Number Of Reportable Segments
NumberOfReportableSegments
|
1 | segment | |
CY2023Q2 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
CY2022Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
CY2023Q2 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
99344798 | shares |
CY2023Q2 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.12 | |
CY2023Q2 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.12 | |
CY2022Q2 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.17 | |
CY2022Q2 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.17 | |
CY2023Q2 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
96685924 | shares |
CY2023Q2 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
96685924 | shares |
CY2022Q2 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
91650950 | shares |
CY2022Q2 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
91650950 | shares |
CY2023Q1 | us-gaap |
Stock Issued During Period Value Employee Stock Ownership Plan
StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
|
7000 | usd |
CY2023Q1 | us-gaap |
Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
|
195000 | usd |
CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-11559000 | usd |
CY2023Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
36590000 | usd |
CY2023Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1424000 | usd |
CY2023Q2 | us-gaap |
Stock Issued During Period Value Employee Stock Ownership Plan
StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
|
178000 | usd |
CY2023Q2 | us-gaap |
Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
|
-7000 | usd |
CY2023Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-11961000 | usd |
CY2023Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
26224000 | usd |
CY2021Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
90707000 | usd |
CY2022Q1 | us-gaap |
Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
|
-342000 | usd |
CY2022Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-16109000 | usd |
CY2022Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
75974000 | usd |
CY2022Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1966000 | usd |
CY2022Q2 | us-gaap |
Stock Issued During Period Value Employee Stock Ownership Plan
StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
|
149000 | usd |
CY2022Q2 | us-gaap |
Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
|
-104000 | usd |
CY2022Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-15940000 | usd |
CY2022Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
62045000 | usd |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-32049000 | usd | |
us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
128000 | usd | |
us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
80000 | usd | |
cris |
Non Cash Lease Expense
NonCashLeaseExpense
|
662000 | usd | |
cris |
Non Cash Lease Expense
NonCashLeaseExpense
|
529000 | usd | |
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
2819000 | usd | |
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
3684000 | usd | |
cris |
Non Cash Imputed Interest Expense Net Of Imputed Interest
NonCashImputedInterestExpenseNetOfImputedInterest
|
-202000 | usd | |
cris |
Non Cash Imputed Interest Expense Net Of Imputed Interest
NonCashImputedInterestExpenseNetOfImputedInterest
|
6000 | usd | |
us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
602000 | usd | |
us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
-575000 | usd | |
us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-589000 | usd | |
us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-829000 | usd | |
us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-1026000 | usd | |
us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
536000 | usd | |
us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-410000 | usd | |
us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-1671000 | usd | |
cris |
Increase Decrease Operating Lease Liability
IncreaseDecreaseOperatingLeaseLiability
|
-557000 | usd | |
cris |
Increase Decrease Operating Lease Liability
IncreaseDecreaseOperatingLeaseLiability
|
-394000 | usd | |
us-gaap |
Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
|
3453000 | usd | |
us-gaap |
Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
|
3102000 | usd | |
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-20067000 | usd | |
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-28947000 | usd | |
us-gaap |
Payments To Acquire Investments
PaymentsToAcquireInvestments
|
28336000 | usd | |
us-gaap |
Payments To Acquire Investments
PaymentsToAcquireInvestments
|
35774000 | usd | |
us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
51425000 | usd | |
us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
61395000 | usd | |
us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
0 | usd | |
us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
364000 | usd | |
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
23089000 | usd | |
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
25257000 | usd | |
us-gaap |
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
|
185000 | usd | |
us-gaap |
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
|
149000 | usd | |
cris |
Payments Of Future Royalty Liability Net Of Imputed Interest
PaymentsOfFutureRoyaltyLiabilityNetOfImputedInterest
|
3043000 | usd | |
cris |
Payments Of Future Royalty Liability Net Of Imputed Interest
PaymentsOfFutureRoyaltyLiabilityNetOfImputedInterest
|
2556000 | usd | |
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-2858000 | usd | |
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-2407000 | usd | |
us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
164000 | usd | |
us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-6097000 | usd | |
CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
20293000 | usd |
CY2021Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
40740000 | usd |
CY2023Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
20457000 | usd |
CY2022Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
34643000 | usd |
CY2023Q2 | cris |
Accrued Issuance Costs
AccruedIssuanceCosts
|
171000 | usd |
CY2022Q2 | cris |
Accrued Issuance Costs
AccruedIssuanceCosts
|
0 | usd |
us-gaap |
Interest Paid Net
InterestPaidNet
|
1424000 | usd | |
us-gaap |
Interest Paid Net
InterestPaidNet
|
2091000 | usd | |
us-gaap |
Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
|
0 | usd | |
us-gaap |
Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
|
-191000 | usd | |
us-gaap |
Nature Of Operations
NatureOfOperations
|
Nature of Business<div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Curis, Inc. is a biotechnology company seeking to develop and commercialize innovative drug candidates to treat cancer. Throughout these Condensed Consolidated Financial Statements, Curis, Inc. and its wholly owned subsidiaries are collectively referred to as “the Company,” “Curis,” “we,” “us,” or “our.”</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company conducts its research and development programs both internally and through strategic collaborations. The Company has prioritized its lead clinical stage drug candidate emavusertib, an orally available small molecule inhibitor of Interleukin-1 receptor associated kinase 4 (“IRAK4”).</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to a collaboration with Genentech Inc. (“Genentech”), a member of the Roche Group, under which Genentech and F. Hoffmann-La Roche Ltd (“Roche”) are commercializing Erivedge® (vismodegib), a first-in-class orally administered small molecule Hedgehog signaling pathway antagonist. Erivedge is approved for the treatment of advanced basal cell carcinoma (“BCC”).</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to an exclusive collaboration agreement with Aurigene Discovery Technologies Limited (“Aurigene”) for the discovery, development and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks common to companies in the biotechnology industry as well as risks that are specific to the Company’s business, including, but not limited to: the Company’s ability to obtain adequate financing to fund its operations; the Company’s ability to advance and expand its research and development programs; the Company’s ability to execute on its overall business strategies; the Company’s ability to obtain and maintain necessary intellectual property protection; development by the Company’s competitors of new or better technological innovations; the Company’s ability to comply with regulatory requirements; the Company’s ability to obtain and maintain applicable regulatory approvals and commercialize any approved product candidates; the ability of the Company and its wholly owned subsidiary, Curis Royalty, LLC (“Curis Royalty”), to satisfy the terms of the royalty interest purchase agreement (the “Oberland Purchase Agreement”) with entities managed by Oberland Capital Management, LLC (the “Purchasers”), and Lind SA LLC (the “Agent”), as collateral agent for the Purchasers; and the Company’s ability to implement a reverse stock split and maintain its current listing on Nasdaq.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s future operating results will largely depend on the progress of drug candidates currently in its development pipeline and the magnitude of payments that it may receive and make under its current and potential future collaborations. The results of the Company’s operations have varied and will likely continue to vary significantly from year to year and quarter to quarter and depend on a number of factors, including, but not limited to the timing, outcome and cost of the Company’s preclinical studies and clinical trials for its drug candidates.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will require substantial funds to maintain research and development programs and support operations. The Company has incurred losses and negative cash flows from operations since its inception. As of June 30, 2023, the Company had an accumulated deficit of $1.2 billion, and for the six months ended June 30, 2023, the Company incurred a net loss of $23.5 million and used $20.1 million of cash in operations. The Company expects to continue to generate operating losses in the foreseeable future. The Company anticipates that its $63.5 million of existing cash, cash equivalents and investments at June 30, 2023, and the net proceeds of approximately $13.9 million from the July Registered Direct discussed below, should be sufficient to fund operations for at least 12 months from the date of filing this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s ability to raise additional funds will depend, among other factors, on financial, economic and market conditions, many of which are outside of its control and it may be unable to raise financing when needed, or on terms favorable to the Company. If necessary funds are not available, the Company will have to delay, reduce the scope of, or eliminate some of its development programs, potentially delaying the time to market for or preventing the marketing of any of its product candidates.</span></div> | ||
CY2023Q2 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-1200000000 | usd |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-23500000 | usd | |
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-20100000 | usd | |
CY2023Q2 | us-gaap |
Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
|
63500000 | usd |
us-gaap |
Use Of Estimates
UseOfEstimates
|
Use of Estimates and AssumptionsThe preparation of the Company’s Condensed Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosure of revenue, expenses and certain assets and liabilities at the balance sheet date. Such estimates include the performance obligations under the Company’s collaboration agreements; the collectability of receivables; the carrying value of goodwill; and the value of certain investments and liabilities. Actual results may differ from such estimates. These interim results are not necessarily indicative of results to be expected for a full year or subsequent interim periods. | ||
CY2022Q4 | us-gaap |
Restricted Cash
RestrictedCash
|
600000 | usd |
CY2023Q2 | us-gaap |
Restricted Cash
RestrictedCash
|
600000 | usd |
CY2023Q2 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
43663000 | usd |
CY2023Q2 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
5000 | usd |
CY2023Q2 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
3000 | usd |
CY2023Q2 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
43665000 | usd |
cris |
Available For Sale Securities Weighted Average Maturity
AvailableForSaleSecuritiesWeightedAverageMaturity
|
P0Y2M12D | ||
CY2022Q4 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
66151000 | usd |
CY2022Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
2000 | usd |
CY2022Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
188000 | usd |
CY2022Q4 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
65965000 | usd |
CY2023Q2 | us-gaap |
Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
|
0 | usd |
CY2022Q2 | us-gaap |
Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
|
0 | usd |
CY2022Q4 | us-gaap |
Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
|
27400000 | usd |
CY2022Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
3152000 | usd |
CY2022Q4 | cris |
Research And Development Costs Current
ResearchAndDevelopmentCostsCurrent
|
762000 | usd |
CY2022Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
38000 | usd |
CY2022Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
5679000 | usd |
CY2023Q2 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
3400000 | usd |
CY2023Q2 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
3700000 | usd |
CY2022Q4 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
3900000 | usd |
CY2022Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
4400000 | usd |
CY2022Q2 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
400000 | usd |
CY2023Q2 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
400000 | usd |
us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
700000 | usd | |
us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
700000 | usd | |
CY2023Q2 | us-gaap |
Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
|
P6Y | |
CY2023Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
8800000 | usd |
CY2023Q2 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
400000 | usd |
us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
700000 | usd | |
CY2022Q2 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
300000 | usd |
us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
600000 | usd | |
CY2023Q2 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.10 | |
CY2019Q1 | cris |
Royalty Purchase Agreement Interest Rate
RoyaltyPurchaseAgreementInterestRate
|
0.061 | |
CY2019Q1 | cris |
Royalty Purchase Agreement Transaction Fees And Closing Costs
RoyaltyPurchaseAgreementTransactionFeesAndClosingCosts
|
600000 | usd |
CY2022Q4 | cris |
Royalty Purchase Agreement Liability Carrying Value
RoyaltyPurchaseAgreementLiabilityCarryingValue
|
49483000 | usd |
cris |
Royalty Purchase Agreement Issuance Costs Capitalized Amortization
RoyaltyPurchaseAgreementIssuanceCostsCapitalizedAmortization
|
-49000 | usd | |
cris |
Royalty Purchase Agreement Accretion Expense
RoyaltyPurchaseAgreementAccretionExpense
|
1271000 | usd | |
cris |
Payments Of Future Royalty Liability
PaymentsOfFutureRoyaltyLiability
|
4467000 | usd | |
CY2023Q2 | cris |
Royalty Purchase Agreement Liability Carrying Value
RoyaltyPurchaseAgreementLiabilityCarryingValue
|
46238000 | usd |
cris |
Collaboration Agreement Numberof Programs Licensed
CollaborationAgreementNumberofProgramsLicensed
|
4 | program | |
cris |
Share Based Compensation Plans
ShareBasedCompensationPlans
|
2 | plan | |
CY2022Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
13673256 | shares |
CY2022Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
3.24 | |
CY2022 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P6Y6M3D | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
5464050 | shares | |
us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
0.71 | ||
us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
10312 | shares | |
us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
0.67 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
1577748 | shares | |
us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
3.35 | ||
CY2023Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
17549246 | shares |
CY2023Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
2.44 | |
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P7Y4M17D | ||
CY2023Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
629000 | usd |
CY2023Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
8859233 | shares |
CY2023Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
3.18 | |
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P5Y7M28D | ||
CY2023Q2 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
|
6000 | usd |
CY2023Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
|
17549246 | shares |
CY2023Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
|
2.44 | |
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
|
P7Y4M17D | ||
CY2023Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
|
629000 | usd |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
0.60 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
2.57 | ||
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P5Y6M | ||
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P5Y6M | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
|
0.035 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
|
0.036 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
|
0.014 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
|
0.025 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
|
1.15 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
|
1.16 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
|
1.10 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
|
1.12 | ||
CY2023Q2 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
|
10900000 | usd |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
0 | usd | |
CY2023Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1424000000 | usd |
CY2022Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1966000 | usd |
us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
2819000000 | usd | |
us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
3684000 | usd |